Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,473 across all filing types
Latest filing 2020-10-19 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a disclosure return related to changes in issued share capital and share buybacks by Ascletis Pharma Inc., submitted to the Stock Exchange of Hong Kong. It details share repurchases, issued shares, prices, and confirmations of compliance with listing rules. The content focuses on share capital changes and repurchase activities rather than financial results, management changes, or legal matters. It is not a full financial report or earnings release but a regulatory disclosure about share capital changes and repurchases. This fits the definition of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares.
2020-10-19 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, issued shares, prices, and confirmations related to compliance with listing rules. The content focuses on reporting share capital changes and share repurchase activities, which aligns with announcements regarding share issues or capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory disclosure about capital changes and share buybacks. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (8589 characters) supports it being a substantive disclosure rather than a brief announcement or certification only.
2020-10-16 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on share repurchases, issue prices, and confirmations related to compliance with listing rules. The content focuses on reporting share capital changes and repurchase activities, which aligns with announcements about share issues or capital changes rather than a full financial report or other types of filings. The document is about disclosing changes in issued share capital and share buybacks, which fits the definition of Share Issue/Capital Change (SHA). The document length is 8413 characters, which is substantive and contains detailed data, not just an announcement of a report. Therefore, the classification is SHA with high confidence.
2020-10-15 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on shares repurchased, confirmations of compliance with listing rules, and detailed tables of share issues and repurchases. The content focuses on reporting share capital changes and share buybacks, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is regulatory in nature, providing disclosure of share capital changes and repurchases as required by the stock exchange rules. This fits the definition of a Share Issue/Capital Change announcement (SHA). The document length (8324 characters) and detailed data support it being a substantive disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is SHA with high confidence.
2020-10-14 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Ascletis Pharma Inc., detailing changes in issued share capital and share buybacks. It includes specific data on shares repurchased, confirmation of compliance with listing rules, and detailed notes on share issues and repurchases. The content focuses on reporting share capital changes and share buybacks, which aligns with announcements regarding share repurchase activities or capital changes. There is no comprehensive financial data or management discussion typical of annual or interim reports, nor is it a simple announcement of a report publication. The document fits the category of a Share Issue/Capital Change filing, as it reports on changes in issued shares and share repurchases under regulatory requirements.
2020-10-12 English
VOLUNTARY ANNOUNCEMENT - GANNEX RECEIVED U.S. IND APPROVAL FOR ITS NASH DRUG CANDIDATE ASC42, AN FXR AGONIST
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the receipt of U.S. IND approval for a drug candidate ASC42. It is a short announcement (2298 characters) that informs about a regulatory milestone related to clinical trials. There is no financial data, no detailed report, no meeting materials, no voting results, no management changes, no earnings or interim report, no audit or legal proceedings information. The document is an announcement of a regulatory event related to drug development, not a financial or governance report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-10-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.